🧬 Aging Wiki

familial-hypercholesterolemia

Properties1
aliasesFH, hereditary hypercholesterolemia, type IIa hyperlipoproteinemia, HeFH, HoFH

14 min read

Familial Hypercholesterolemia

The most clinically important Mendelian dyslipidemia and the original proof-of-concept for the causal role of LDL-cholesterol in atherosclerosis. FH is an autosomal-codominant disorder of LDL clearance causing markedly elevated LDL-C from birth, accelerated atherosclerosis, and premature cardiovascular death — particularly coronary artery disease and, in severe cases, aortic stenosis. Its importance extends beyond clinical genetics: FH patients are the natural experiment that established cumulative LDL exposure as causal for ASCVD 1, underpinning the entire modern lipid-lowering framework.

Global heterozygous FH (HeFH) prevalence is ~1:313 by the most comprehensive meta-analysis (>10.9 million subjects) 2, making it far more common than previously assumed (~1:500 Goldstein-Brown era estimate). Despite this, most affected individuals are undiagnosed before their first cardiovascular event 3.

Genetic architecture

FH arises from loss-of-function (or gain-of-function) variants disrupting hepatic LDL receptor (LDLR) pathway:

GeneFrequency among genetically-confirmed FHMechanism
ldlr~85–90% of casesLoss-of-function; impaired LDL particle uptake
apob~5–10% of casesTypically Arg3500Gln (R3500Q); APOB-100 fails to bind LDLR
pcsk9~1–3% of casesGain-of-function; accelerates LDLR degradation in endosomes
LDLRAP1Rare (~<1%)Autosomal recessive hypercholesterolemia (ARH); impairs LDLR clustering in coated pits

Frequency estimates are approximate; exact proportions depend on population and diagnostic ascertainment 4. Novel pathogenic variants in APOE (rare) and digenic causes also documented.

PCSK9 founding mutations (Abifadel 2003)

The PCSK9 locus was identified as a third FH gene by Abifadel et al. in two French pedigrees carrying S127R and F216L gain-of-function variants — establishing that PCSK9 gain-of-function mimics LDLR loss-of-function phenotypically 5. This mechanistic insight directly motivated the development of PCSK9 inhibitors as a therapeutic class.

LDLR mutation classes (Goldstein-Brown schema)

The five-class functional classification of LDLR mutations predicts both phenotype severity and therapeutic response 6:

ClassDefectMechanismNotes
1 — NullNo LDLR protein producedPromoter or frameshift mutationsWorst phenotype; minimal statin response
2 — Transport-defectiveLDLR synthesized but retained in ERMisfolding prevents ER→Golgi exportModerate–severe; statins increase immature LDLR accumulation in ER
3 — Binding-defectiveLDLR reaches cell surface but cannot bind LDLMutation in ligand-binding domainModerate phenotype
4 — Internalization-defectiveLDLR binds LDL at surface but cannot enter coated pitsMutation in cytoplasmic tailModerate
5 — Recycling-defectiveLDLR fails to dissociate from ligand in endosome → both degradedMutation prevents acid-induced releaseSurface LDLR can be upregulated by statins → better statin response than Class 1

Clinical implication: Patients with null LDLR mutations (Class 1) achieve worse LDL-C lowering on statins than those with defective mutations or no identified mutation. In a Brazilian HeFH cohort (n=156), only 22.5% of null-mutation carriers reached LDL-C target vs 27.1% of defective-mutation carriers and 47.4% of those with no identified mutation; null mutations were independently associated with higher odds of not reaching LDL-C target (OR 9.07, 95% CI 1.41–58.16, p=0.02) 7. The mechanism is that statins upregulate LDLR transcription via the functional allele — patients with null alleles have no receptor to upregulate. needs-replication — single-center cohort study.

Heterozygous FH (HeFH)

Prevalence: 1:313 globally (95% CI 1:384 to 1:256) by meta-analysis; the general-population subanalysis covered 44 studies and 10.9 million subjects from a 104-study total meta-analysis 2. This supersedes the older 1:500 estimate. Prevalence is higher in founder populations (Afrikaners, Lebanese Christians, French Canadians, Ashkenazi Jews, Finns: up to 1:67–100 in some founder groups) and lower in some East Asian populations.

LDL-C: Typically 200–400 mg/dL untreated (vs population mean ~130 mg/dL).

Clinical features:

  • Tendon xanthomas (Achilles, dorsal hand/finger extensor tendons) — pathognomonic when present; absent in many HeFH patients
  • Corneal arcus (premature; <45 years in men, <50 in women — less specific)
  • Xanthelasma (periorbital lipid deposits — low specificity for FH)
  • Premature CHD: men typically by 40s–50s, women 50s–60s untreated
  • Family history: first-degree relatives with premature CAD and/or elevated LDL

Underdiagnosis: Estimates suggest <20–25% of HeFH individuals globally are diagnosed before a cardiovascular event 3. Most clinical lipid panels do not flag LDL-C in isolation as FH unless it exceeds 190 mg/dL, and clinical xanthomas are absent in many patients.

Homozygous FH (HoFH)

HoFH arises from inheriting pathogenic variants from both parents (true homozygotes or compound heterozygotes). True nullizygous homozygotes (Class 1/1) have virtually no functional LDLR and the most severe phenotype.

Prevalence: Previously estimated at ~1:1,000,000; Tromp 2022 uses ~1:300,000 as the worldwide estimate; the EAS Consensus Panel (cited in Abifadel 2023) derives 1:160,000–300,000 by Hardy-Weinberg calculation from HeFH prevalence 84.

LDL-C: 600–1000 mg/dL untreated in null/null; somewhat lower in compound heterozygotes with residual receptor function.

Clinical features:

  • Tendon xanthomas, cutaneous (planar) xanthomas, and xanthelasma from childhood or infancy
  • Corneal arcus from childhood
  • Aortic stenosis — lipid deposition in aortic valve cusps, creating obstructive physiology in the 2nd–3rd decade of life
  • Untreated: major cardiovascular events and/or death typically by 3rd decade

International registry data (751 HoFH patients, 38 countries): ASCVD or aortic stenosis present in 9% of patients already at the time of diagnosis; median age of first CV event was a decade earlier in non-high-income vs high-income countries (24.5 vs 37.0 years) 8. Patients globally are “diagnosed too late, undertreated, and at high premature ASCVD risk.”

Diagnostic criteria

Three clinical scoring systems are in current use; genetic testing is increasingly the reference standard:

Dutch Lipid Clinic Network (DLCN) criteria

Point-based scoring system incorporating family history (first-degree relative with premature CHD or known FH), personal history of premature ASCVD, physical exam findings (tendon xanthomas, corneal arcus), and LDL-C levels. Scoring thresholds: ≥8 = definite FH; 6–7 = probable FH; 3–5 = possible FH; <3 = unlikely FH. Most widely used in European and research contexts. LDL-C thresholds for efficient genetic testing selection: ~5.79 mmol/L (<40 yr) and ~6.7 mmol/L (≥40 yr) 9.

Simon Broome criteria (UK)

Simpler two-tier classification (definite vs possible FH) based on total cholesterol, LDL-C, family history, physical findings, and genetic confirmation. Used by NHS cascade screening programs.

MEDPED (Make Early Diagnoses, Prevent Early Deaths)

LDL-C thresholds adjusted for age and first-degree relative status to diagnose FH in index cases and relatives. Used primarily in US family cascade screening programs.

Genetic confirmation is preferred over clinical scoring when available, as clinical criteria have significant false-positive and false-negative rates; a positive genetic result enables more confident cascade screening of relatives 3.

Treatment landscape

HeFH treatment — stepwise intensification

Treatment goal: LDL-C <70 mg/dL (high-risk); <55 mg/dL (very-high-risk with established ASCVD or other high-risk features). Early treatment is paramount given the cumulative-exposure model.

  1. High-intensity statin — rosuvastatin 20–40 mg/day or atorvastatin 40–80 mg/day. Reduces LDL-C 50–60%. Upregulates functional LDLR allele via srebp-2-mediated transcriptional activation of hmgcr and ldlr. Response depends on mutation class (see above).
  2. Ezetimibe — adds ~18–20% further LDL-C reduction by blocking NPC1L1 internalization, reducing intestinal cholesterol absorption and stimulating hepatic LDLR expression. Standard add-on if statin alone insufficient. IMPROVE-IT 2015 validates additive CV benefit.
  3. PCSK9 inhibitors (alirocumab, evolocumab) — monoclonal antibodies blocking pcsk9-mediated LDLR degradation; add 50–60% LDL-C reduction on top of maximal statin + ezetimibe. Clinical standard for FH with residual LDL elevation or established ASCVD.
  4. Bempedoic acid — ATP-citrate lyase (ACLY) inhibitor; liver-specific bioactivation by ACSVL1 → no SAMS; reduces LDL-C ~18% monotherapy, more in combination. CLEAR Outcomes 2023 (HR 0.87) — useful in statin-intolerant FH patients.
  5. Inclisiran — siRNA targeting PCSK9 mRNA; twice-yearly injection; similar LDL-C reduction to antibody-class PCSK9i; now approved in multiple regions.

HoFH treatment — LDLR-dependent vs LDLR-independent

The distinction between LDLR-defective (residual function) and LDLR-null genotypes is critical for therapy selection:

LDLR-defective HoFH (Class 2–5 compound heterozygotes with some residual LDLR): statins + ezetimibe + PCSK9i are worthwhile; response is limited but meaningful.

LDLR-null/null HoFH (Class 1/1): minimal response to statins or PCSK9i; require LDLR-independent approaches:

  • Evinacumab (ANGPTL3 inhibitor) — monoclonal antibody blocking ANGPTL3, which normally inhibits lipoprotein lipase and endothelial lipase; evinacumab reduces LDL-C via an LDLR-independent mechanism (reduced VLDL production + enhanced TG-rich lipoprotein clearance). In the ELIPSE HoFH Phase 3 trial (n=65, 2:1 randomization, 15 mg/kg IV q4w), reduced LDL-C by 47.1% vs +1.9% for placebo (between-group difference −49.0 percentage points, 95% CI −65.0 to −33.1, p<0.001) independent of LDLR genotype 10. FDA-approved for HoFH. Current standard-of-care for null/null patients.
  • Lomitapide — microsomal triglyceride transfer protein (MTP) inhibitor; blocks hepatic ApoB-containing VLDL assembly upstream of LDLR, reducing LDL-C ~50% (Cuchel 2013 Lancet, n=29 HoFH); dose-limiting hepatic steatosis (mean liver fat 1.0% → 8.6% NMRS at 26 wk); used as add-on therapy in HoFH.
  • LDL apheresis — extracorporeal removal of LDL particles; reduces LDL-C 50–75% acutely; biweekly sessions; indicated as adjunct for refractory HoFH or as bridge to other therapy.
  • Orthotopic liver transplant — transplants LDLR-competent hepatocytes, normalizing LDL clearance; reserved for most severe refractory cases.
  • Gene therapy / base editing: Verve VERVE-101 (PCSK9 base-editing) targets hepatic PCSK9 permanently to remove the degradation signal on LDLR; Phase 1b data pending; potential future standard for HoFH and ultra-high-risk HeFH. needs-replication

Cumulative LDL exposure model

FH is the strongest natural experiment for LDL causality. Unlike Mendelian randomization studies (which capture average population-level genetic variation), FH subjects are exposed to 2–5× normal LDL concentrations continuously from birth. Coronary artery disease risk scales with cumulative exposure (LDL-C × years).

Key evidence: Among FH patients, every 75 mmol/L·years of cumulative LDL-C exposure was associated with a doubling of percent atheroma volume; even early-treated FH patients showed substantially higher plaque burden than controls, emphasizing that lifetime exposure — not just current LDL — determines ASCVD risk 1.

The World Heart Federation Cholesterol Roadmap explicitly frames the goal of treatment as reducing cumulative apoB exposure over a lifetime, with FH as the motivating model 11.

This framing has clinical implications: earlier treatment initiation (including pediatric treatment of FH children) offers disproportionate benefit relative to late-stage intervention, because it truncates the exposure × time integral. FH provides the rationale for aggressive early LDL lowering even in younger adults with genetically elevated LDL.

Genetic / cascade screening

First-degree relatives of an FH index case have a 50% prior probability of carrying the pathogenic variant (autosomal codominant inheritance). Cascade screening — systematic genetic or clinical testing of relatives of confirmed FH cases — is cost-effective:

  • Netherlands DECON program (1994–2014): >28,000 FH patients identified via national cascade program before 2014 transition to healthcare-integrated approach; regulatory changes limiting active family outreach reduced detection rates post-2014 12
  • Spain national cascade program: cost-effectiveness analysis showed €29,608/QALY gained (dominant from societal perspective), preventing 847 coronary events and 203 deaths in a 9,000-patient cohort over 10 years 13
  • Systematic reviews conclude cascade screening is cost-effective in most settings 14

needs-replication — international uptake data for cascade screening programs; rates vary enormously by country and remain poorly characterized outside Europe.

Hallmark mapping

FH is an accelerated-aging phenotype for vascular biology — it compresses the normal lifetime LDL exposure trajectory by delivering 3–5× the physiological LDL load from birth. The molecular pathway from elevated ApoB → endothelial retention → oxidative modification → foam cell formation → atherosclerosis is the same as in non-FH ASCVD.

  • chronic-inflammation — SASP-like foam cell and VSMC senescence in plaques; elevated circulating CRP and inflammatory cytokines; senescent macrophage accumulation may be enriched by the high-ApoB environment
  • altered-intercellular-communication — modified LDL (oxLDL) acts as a paracrine signal inducing endothelial dysfunction, monocyte recruitment, and vascular smooth muscle cell phenotypic switching; the ApoB/LDLR signaling axis is disrupted by every FH-causing variant

Aging-relevance

FH accelerates the vascular aging trajectory without altering the molecular aging rate elsewhere — making it a model for decomposing vascular aging from systemic aging. The senescent foam cell accumulation in FH plaques provides a cellular bridge to cellular-senescence as a hallmark. FH subjects who survive to 65+ represent a selected cohort who escaped premature mortality, often due to milder variant classes or earlier treatment — their longitudinal cardiovascular data inform the relationship between prior LDL exposure and residual risk in older adults.

Limitations and gaps

  • Diagnostic underascertainment — the majority of the ~1:313 globally affected individuals are undiagnosed; lipid cascade screening is not standard in most countries outside the Netherlands, UK, and Spain. needs-human-replication
  • Mutation-class phenotyping — comprehensive mutation-class-to-clinical-outcome data are sparse; most FH registries lack functional characterization of LDLR variants
  • HoFH prevalence — revised estimates (1:160,000–300,000) lack large prospective denominator data; primarily registry-derived
  • Pediatric treatment — statins in children with FH are guideline-recommended but long-term (>20 year) safety data in pediatric starters are not yet available; trial follow-up too short to fully characterize cumulative benefit vs risk long-term-unknown
  • PCSK9 gain-of-function spectrum — PCSK9 GoF mutation frequency in FH varies by population; functional characterization of rare PCSK9 variants is incomplete needs-replication
  • Atherosclerosis regression — even with optimal LDL-C lowering, FH patients carry substantially elevated plaque burden; optimal strategies for regression (vs stabilization) are unclear no-mechanism

Footnotes

Footnotes

  1. doi:10.1093/eurjpc/zwae028 · Ibrahim S, Reeskamp LF, de Goeij JN, Hovingh GK et al. · Eur J Prev Cardiol 2024 · observational · n=90 genetically confirmed FH patients + 45 controls (mean age 41 yr, 38% female) · coronary plaque prevalence 51% (46/90) vs 22% (10/45), OR 3.66 (95% CI 1.62–8.27); every 75 mmol/L·years cumulative LDL-C exposure associated with doubling of percent atheroma volume; mean cumulative LDL-C 181 ± 54 mmol/L·yr (FH) vs 105 ± 33 mmol/L·yr (controls); even early-treated FH patients showed excess atherosclerosis · confirms cumulative-LDL causal model · not_oa (PDF download failed) ↩ ↩2

  2. doi:10.1016/j.jacc.2020.03.057 · Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG · J Am Coll Cardiol 2020 · 104 studies total across 4 population categories; general-population subanalysis: n=10,921,310 subjects, 44 studies · meta-analysis · FH prevalence 0.32% (1:313, 95% CI 1:384–1:256) in general population; 3.2% in ischemic heart disease; 6.7% in premature IHD · supersedes older 1:500 estimate · not_oa (PDF download failed) ↩ ↩2

  3. doi:10.1016/j.jacc.2018.05.044 · Sturm AC, Knowles JW, Gidding SS et al. · J Am Coll Cardiol 2018 · expert consensus · recommends genetic testing as standard care; cascade testing of first-degree relatives; early therapy initiation improves risk stratification · not_oa (no local PDF) ↩ ↩2 ↩3

  4. doi:10.1111/joim.13577 · Abifadel M, Boileau C · J Intern Med 2023 · review · genetic and molecular architecture of FH; covers LDLR, APOB, PCSK9, APOE, LDLRAP1; notes FH “is still largely underdiagnosed worldwide” · local PDF: (local PDF) ↩ ↩2

  5. doi:10.1038/ng1161 · Abifadel M, Varret M, Rabès JP et al. · Nature Genetics 2003;34:154–156 · in-vivo genetic · n=2 French pedigrees (HC92 carrying S127R in exon 2; HC60 carrying F216L in exon 4) · identifies PCSK9 gain-of-function S127R and F216L mutations as a third cause of autosomal dominant FH beyond LDLR and APOB · local PDF: (local PDF) ↩

  6. doi:10.1002/humu.22721 · Etxebarria A, Benito-Vicente A, Palacios L et al. · Human Mutation 2015 · functional characterization · classifies 7 LDLR variants across Classes 2–5; statin response better in Class 2 vs Class 5 variants · model: iPSC/in-vitro ↩

  7. doi:10.1016/j.atherosclerosis.2013.12.028 · Santos PCJ Lima, Morgan AC, Jannes CE et al. · Atherosclerosis 2014 · observational · n=156 Brazilian HeFH patients (null mutations n=40, defective n=59, no identified mutation n=57) · LDL-C target achievement: null 22.5%, defective 27.1%, no identified mutation 47.4% (p=0.02) · null mutations independently associated with higher odds of not reaching LDL-C target (OR 9.07, 95% CI 1.41–58.16, p=0.02) · not_oa (PDF download failed) ↩

  8. doi:10.1016/S0140-6736(21)02001-8 · Tromp TR, Hartgers ML, Hovingh GK et al. · Lancet 2022 · retrospective cohort · n=751 HoFH patients (52% female), 38 countries, 88 institutions · 9% already had ASCVD or aortic stenosis at diagnosis; median age of first MACE 24.5 yr (IQR 17.0–34.5, non-HIC) vs 37.0 yr (IQR 29.0–49.0, HIC); paper uses ~1:300,000 as worldwide HoFH prevalence estimate · local PDF: (local PDF))02001-8.pdf ↩ ↩2

  9. doi:10.1016/j.atherosclerosis.2016.03.025 · Mickiewicz A, Chmara M, Futema M et al. · Atherosclerosis 2016 · DLCN validation in Poland · LDL-C thresholds for efficient genetic testing: 5.79 mmol/L (<40 yr), 6.7 mmol/L (≥40 yr) · archive status: pending ↩

  10. doi:10.1056/NEJMoa2004215 · Raal FJ, Rosenson RS, Yancopoulos GD et al. · N Engl J Med 2020;383:711–720 · randomized · n=65 HoFH patients (2:1 evinacumab 15 mg/kg IV q4w vs placebo) · primary endpoint week 24: LDL-C −47.1% (evinacumab) vs +1.9% (placebo); between-group difference −49.0 percentage points (95% CI −65.0 to −33.1; p<0.001); absolute reduction −132.1 mg/dL; effective in null/null genotypes · ELIPSE HoFH Phase 3 trial; FDA-approved for HoFH ↩

  11. doi:10.5334/gh.1154 · Ray KK, Ference BA, Séverin T et al. · Global Heart 2022 · World Heart Federation Cholesterol Roadmap 2022 · advocates reducing cumulative apoB exposure as primary ASCVD prevention strategy; FH used as proof-of-concept model for LDL causality · local PDF: (local PDF) ↩

  12. doi:10.1016/j.atherosclerosissup.2017.05.019 · Louter L, Defesche J, Roeters van Lennep J · Atherosclerosis Suppl 2017 · Netherlands DECON program 1994–2014: >28,000 FH patients identified; post-2014 regulatory change limiting active family outreach reduced new detections · not_oa ↩

  13. doi:10.1016/j.jacl.2017.01.002 · Lázaro P, Pérez de Isla L, Watts GF et al. · J Clin Lipidol 2017 · cost-effectiveness · n=9,000-patient cohort, Spain · prevented 847 coronary events, 203 deaths over 10 yr; €29,608/QALY gained (dominant from societal perspective) · not_oa ↩

  14. doi:10.7416/ai.2017.2178 · Rosso A, Pitini E, D’Andrea E et al. · Ann Ig 2017 · systematic review · 7 economic evaluations 2002–2015 · cascade screening cost-effective in most settings · not_oa ↩

Graph View

Backlinks